2-mercaptobutanol | 33959-23-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醇
• 英文名称: 2-mercaptobutanol
• 英文别名: 2-mercaptobutan-1-ol；methyl (R)-2-mercaptopropan-1-ol；2-mercapto-1-hydroxybutane；1-hydroxybutane-2-thiol；(RS)-2-mercapto-butan-1-ol；2-sulfanylbutan-1-ol
• CAS: 33959-23-8
• 化学式: C₄H₁₀OS
• 分子量: 106.189
• InChiKey: UVSYLHMNAUJEFX-UHFFFAOYSA-N

物化性质

• 沸点：
  171.3±23.0 °C(Predicted)
• 密度：
  0.997±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  6
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-mercaptobutanol 生成 (R)-2-((5-5-nitropyridin-2-yl)dithiocyclohexyl)propan-1-ol
  参考文献：
  名称：

  ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

  摘要：

  Disclosed are an antibody drug conjugate, a preparation method therefor and an application thereof, which are in particular, a conjugate of an anti-PD-L1 antibody and a TLR7 and/or TLR8 agonist, a pharmaceutical composition thereof, a preparation method therefor and an application thereof. In the present invention, a modified anti-PD-L1 antibody having mutated cysteine is obtained by means of gene editing, basically retains the structure of the original antibody, and may be used for the construction of antibody drug conjugates. By means of anti-tumor experiments, it has been discovered that the obtained antibody drug conjugate has good activity, such as strong anti-tumor activity, which may significantly improve the survival rate of tumor-bearing animals, and significantly reduce toxicity. Moreover, the antibody drug conjugate is less burdensome on the bodies of test animals, which greatly reduces the minimum effective dose of small molecular drugs when used alone, expands the therapeutic window thereof, is expected to be used in the development of therapeutic drugs for various diseases (such as tumors, viral diseases such as hepatitis B, etc.), and has good application prospects and value.

  公开号：

  US20240252670A1
• 作为产物：
  描述：

  ethyl 2-(ethyloxythiocarbonylthio)butyrate 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 5.0h， 以98%的产率得到2-mercaptobutanol
  参考文献：
  名称：

  Wu, Shao-Yong; Hirashima, Akinori; Takeya, Ryuko, Agricultural and Biological Chemistry, 1988, vol. 52, # 11, p. 2911 - 2918

  摘要：

  DOI：

文献信息

• Asymmetric syntheses of α-mercapto carboxylic acid derivatives by dynamic resolution of N-methyl pseudoephedrine α-bromo esters
  作者：Jiyoun Nam、Sang-kuk Lee、Kee Yong Kim、Yong Sun Park

  DOI：10.1016/s0040-4039(02)02020-8

  日期：2002.11

  Dynamic resolution of N-methyl pseudoephedrine α-bromo esters in nucleophilic substitution reaction with trityl thiol has been successfully used for the asymmetric preparation of α-mercapto carboxylic acid derivatives up to 97:3 dr. The best results are obtained when α-bromo esters are allowed to equilibrate to the thermodynamic ratios before the addition of sulfur nucleophile. We have shown that the

  在与三苯甲基硫醇的亲核取代反应中，N-甲基伪麻黄碱α-溴代酯的动态拆分已成功用于不对称制备高达97：3 dr的α-巯基羧酸衍生物。当在添加硫亲核试剂之前使α-溴酸酯达到热力学比平衡时，可获得最佳结果。我们已经表明，手性助剂可以通过还原裂解和酸性醇解反应除去，以分别提供β-三苯甲基硫醇15和α-三苯甲基硫醇酯16，而没有可检测的消旋作用。
• Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
  申请人：Luecking Ulrich

  公开号：US20050176743A1

  公开（公告）日：2005-08-11

  This invention relates to pyrimidine derivatives of general formula I in which Q, R 1 , R 2 , R 3 , R 4 , R 5 , X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.

  本发明涉及通式I的嘧啶衍生物，其中Q，R1，R2，R3，R4，R5，X和m具有描述中所含的含义，作为细胞周期蛋白依赖性激酶和VEGF受体酪氨酸激酶的抑制剂，它们的制备以及它们作为治疗各种疾病的药物的用途。
• SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS
  申请人：Lücking Ulrich

  公开号：US20100076000A1

  公开（公告）日：2010-03-25

  This invention relates to pyrimidine derivatives of general formula I in which Q, R 1 , R 2 , R 3 , R 4 , R 5 , X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.

  本发明涉及通式I的嘧啶衍生物，其中Q、R1、R2、R3、R4、R5、X和m的含义如描述中所含，作为细胞周期蛋白依赖性激酶和VEGF受体酪氨酸激酶的抑制剂，其制备以及其作为治疗各种疾病的药物的用途。
• Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
  申请人：Lücking Ulrich

  公开号：US08507510B2

  公开（公告）日：2013-08-13

  This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.

  本发明涉及通式I的嘧啶衍生物，其中Q，R1，R2，R3，R4，R5，X和m的含义如说明书所述，作为细胞周期依赖性激酶和VEGF受体酪氨酸激酶的抑制剂，以及它们的制备和用作治疗各种疾病的药物。
• WU, SHAO-YONG;HIRASHIMA, AKINORI;TAKEYA, RYUKO;ETO, MORIFUSA, ARG. AND BIOL. CHEM., 52,(1988) N1, C. 2911-2917
  作者：WU, SHAO-YONG、HIRASHIMA, AKINORI、TAKEYA, RYUKO、ETO, MORIFUSA

  DOI：——

  日期：——